Natixis Advisors LLC Purchases 7,118 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Natixis Advisors LLC grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 19.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,929 shares of the medical equipment provider's stock after buying an additional 7,118 shares during the quarter. Natixis Advisors LLC owned 0.06% of Lantheus worth $3,447,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LNTH. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after acquiring an additional 1,269,900 shares in the last quarter. Norges Bank acquired a new position in shares of Lantheus during the 4th quarter worth approximately $29,956,000. Swedbank AB acquired a new position in shares of Lantheus during the 1st quarter worth approximately $26,346,000. Nomura Holdings Inc. raised its stake in shares of Lantheus by 105.3% during the 4th quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider's stock worth $1,282,000 after purchasing an additional 407,507 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its stake in shares of Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after buying an additional 394,837 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of Lantheus stock traded down $1.38 during trading on Monday, reaching $100.60. 642,365 shares of the company's stock were exchanged, compared to its average volume of 1,034,073. The firm's 50-day moving average price is $102.61 and its 200 day moving average price is $81.60. The company has a market cap of $6.98 billion, a P/E ratio of 15.36 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm's revenue was up 22.5% compared to the same quarter last year. During the same period last year, the company posted $1.40 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of recent analyst reports. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. JMP Securities reduced their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Finally, Leerink Partners boosted their target price on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $126.00.

Insider Activity

In related news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the sale, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total transaction of $27,201.57. Following the sale, the chief accounting officer now directly owns 62,557 shares in the company, valued at approximately $4,990,171.89. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,193 shares of company stock worth $3,949,202. Insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.